When the relationship between CDK 5 expression and other parameters was concerned in the patients with NSCLCs, higher CDK5 expression positive rate appeared in the advanced stages (III and IV) (66 %, 35/53) compared with the early stages (I and II) (48.3 %, 138/286, P = 0.018, Table 4) and the similar result was found in lymph node metastasis (76.5 %, 88/115) as compared to non-lymph node metastasis (37.9 %, 85/224, P < 0.001, Table 4). The gene discussed is CDK5; the disease is metastatic malignant neoplasm in the lymph nodes.